Comparative Pharmacology
Head-to-head clinical analysis: FLUTAMIDE versus NILANDRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTAMIDE versus NILANDRON.
FLUTAMIDE vs NILANDRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen; competitively inhibits androgen binding to androgen receptors, thereby blocking androgen action in target tissues.
Competitive inhibitor of androgen binding to androgen receptors, reducing androgen-mediated growth of prostate cancer cells. Also inhibits testicular and adrenal androgen synthesis.
250 mg orally every 8 hours. Total daily dose: 750 mg.
300 mg orally three times a day.
None Documented
None Documented
Flutamide has an initial half-life of about 5–6 hours; its active metabolite, 2-hydroxyflutamide, has a terminal elimination half-life of 8–10 hours, supporting twice-daily dosing for steady-state concentrations.
Clinical Note
moderateFlutamide + Digoxin
"Flutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFlutamide + Digitoxin
"Flutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFlutamide + Deslanoside
"Flutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFlutamide + Acetyldigitoxin
"Flutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 7-8 hours; clinically relevant for twice-daily dosing.
Primarily renal (approximately 98% of absorbed dose as metabolites, with ~4.5% as the active metabolite 2-hydroxyflutamide); less than 1% excreted unchanged; biliary/fecal elimination is minimal (<1%).
Renal: 55-60% as unchanged drug; fecal: 20-30% as metabolites; biliary: minor (<10%).
Category D/X
Category C
Antiandrogen
Antiandrogen